Core Biopsy

PROCEDURE9 trials

Sponsors

Hoosier Cancer Research Network, Yale University, Mayo Clinic, National Cancer Institute (NCI), Northwestern University

Conditions

Advanced Malignant Solid NeoplasmBorderline Resectable Pancreatic AdenocarcinomaBreast CancerCancer SurvivorChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined SignificanceDuctal Breast Carcinoma In SituHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Phase 1

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

RecruitingNCT05053971

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma +6

Start: 2022-11-16End: 2026-07-01Target: 49Updated: 2026-04-03

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

RecruitingNCT05688215

Jonsson Comprehensive Cancer CenterBorderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma

Start: 2023-03-07End: 2027-03-02Target: 56Updated: 2026-01-15

Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

RecruitingNCT03418038

Mayo ClinicChronic Myelomonocytic Leukemia, Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements +5

Start: 2018-03-23End: 2033-11-02Target: 80Updated: 2026-03-18

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Active, not recruitingNCT03880019

National Cancer Institute (NCI)Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Uterine Corpus Leiomyosarcoma

Start: 2019-08-19End: 2026-11-12Updated: 2025-12-03

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

Active, not recruitingNCT04009044

Northwestern UniversityCancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma

Start: 2020-02-17End: 2026-06-25Target: 156Updated: 2025-10-09

Unknown Phase

Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer

TerminatedNCT00537173

Hoosier Cancer Research NetworkBreast Cancer

Start: 2007-09-30End: 2009-08-31Updated: 2017-01-25

Breast Cancer Molecular Analysis Protocol

CompletedNCT01855503

Yale UniversityMetastatic Breast Cancer

Start: 2013-05-31Updated: 2016-11-17

Cryoablation for the Treatment of Metastatic Cancer

Active, not recruitingNCT04150939

M.D. Anderson Cancer CenterMetastatic Malignant Neoplasm

Start: 2019-12-23End: 2026-08-31Updated: 2026-02-17

Effectiveness of Core-Needle US Guided Biopsy as Primary Tool For Diagnosis of Thyroid Nodules

CompletedNCT04759053

Kafrelsheikh UniversityThyroid Diseases, Thyroid Gland; Node, Thyroid Nodule

Start: 2017-01-01End: 2018-02-01Updated: 2021-02-17

Related Papers

LS1781 (Arm E): Phase II clinical trial to assess the safety and efficacy of high dose IV ascorbic acid with decitabine in newly diagnosed TET2 mutant chronic myelomonocytic leukemia (CMML)

Blood2025-11-03

Variability in interventional trials in clonal haematopoiesis

Blood2025-11-03

Phase II Trial Assessing Safety and Preliminary Efficacy of High-Dose Intravenous Ascorbic Acid and Decitabine in <i>TET2</i>-Mutant Chronic Myelomonocytic Leukemia

Blood2024-11-052 citations

High-dose IV ascorbic acid therapy for patients with CCUS with <i>TET2</i> mutations

Blood2024-10-0111 citations

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with <i>TET2</i> Mutant Clonal Cytopenias

Blood2023-11-023 citations

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with <i>TET2</i> Mutant Clonal Cytopenias of Undetermined Significance

Blood2022-11-152 citations

Correlative results from NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Journal of Clinical Oncology2022-06-015 citations

Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with <i>TET2-</i>mutant clonal cytopenias of undetermined significance.

Journal of Clinical Oncology2022-06-013 citations

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Journal of Clinical Oncology2021-05-2011 citations

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

Journal of Clinical Oncology2020-05-206 citations